Company Description
Melt is a clinical stage pharmaceutical company focused on the development and commercialization of proprietary non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient and in-office settings.
We intend to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway for these proprietary, patented small-molecule product candidates, where possible.
The core intellectual property we own is a patented series of combination non-opioid sedation drug formulations that we believe have multiple clinical applications for potential indications of use.
We have compiled a unique pipeline of product candidates in various stages of development. Our lead product candidate, MELT-300, was acquired from Harrow, and our other two product candidates, MELT-210 and MELT-400, were developed internally.
MELT-300, our lead product candidate, which is a fixed dose combination of midazolam and ketamine in a fast-dissolving tablet that is administered sublingually for procedural sedation and analgesia during cataract surgery.
We are developing MELT-300 as a product candidate for FDA approval. We began enrolling our single, pivotal Phase 2 study during the fourth quarter of 2021.
| Country | United States |
| Founded | 2019 |
| Industry | Health Care |
| Sector | Pharmaceuticals |
| Employees | 3 |
| CEO | Larry Dillaha, M.D. |
Contact Details
Address: 6 Cadillac Drive, Suite 320 Brentwood, TN 37027 United States | |
| Phone | (615) 733-4730 |
| Website | meltpharma.com |
Stock Details
| Ticker Symbol | MELT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001767398 |
| Employer ID | 61-1888986 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Larry Dillaha, M.D. | Chief Executive Officer and Director |
| D. Bradford Osborne | Chief Financial Officer |
| Alison Bauerlein | Director |
| Mark Baum | Chairman of the Board of Directors |
| John Berdahl, M.D. | Director |
| J. Andy Corley | Lead Independent Director |
| Arthur Laffer, Ph.D. | Director |
| Herman Williams | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2024 | D/A | Filing |
| Mar 11, 2024 | D/A | Filing |
| Feb 12, 2024 | D/A | Filing |
| Jan 9, 2024 | D/A | Filing |
| Dec 11, 2023 | D/A | Filing |
| Nov 13, 2023 | D/A | Filing |
| Oct 13, 2023 | D/A | Filing |
| Sep 12, 2023 | D/A | Filing |
| Aug 11, 2023 | D | Notice of Exempt Offering of Securities |
| Jan 4, 2023 | RW | Filing |